Recent studies have centered on the overlap of GLP-1|GIP|GCGR activator therapies and DA neurotransmission. While GCGR agonists are widely employed for managing type 2 T2DM, their potential effects on motivation circuits, specifically influenced by dopamine networks, are attracting considerable f